Save your place

Sign in to WhoBought

Please try again later.

Invesco's Clearside Biomedical, Inc. (CLSD) position

Not anymore: Invesco fully exited CLSD in Q4 2021. The position peaked at an amount we cannot price in Q3 2021.
View full portfolio →
Value at exit
an amount we cannot price
Shares at exit
277K
Quarter-end price
No quarter-end price available

Average buy price is hidden here because at least one covered purchase quarter has no usable local mean price.

CLSD price vs Invesco's position

Dates
Average closing price · filing quarter
Price range · filing quarter

Every quarterly change

Quarter Action Shares change Est. value change Δ Own Shares held Filing date
Q4 2021 Exited −277K −100.0% 0 Feb 14, 2022
Q3 2021 New +277K 277K Nov 15, 2021
Data through Q4 2021 · filed Feb 14, 2022
2 grouped rows from 2 quarters

More Invesco positions

Common questions

Does Invesco own CLSD?

Not currently. Invesco fully exited CLSD in Q4 2021, and the complete history is above. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

When did Invesco buy CLSD?

Invesco first disclosed a CLSD position in Q3 2021; every quarterly buy and sell since is in the table above. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

Did Invesco sell CLSD?

Yes. Invesco reduced and then fully exited CLSD by Q4 2021; the reductions are in the table above. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

How many shares of CLSD does Invesco own?

None as of the latest filing: Invesco has exited CLSD. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

What price did Invesco pay for CLSD?

Invesco began building the CLSD position before our 13F history starts, so an exact average buy price cannot be estimated without understating it. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

How are the estimated trade prices calculated?

13F filings disclose quarter-end holdings, not trade dates or execution prices. These estimates use each covered quarter's average market price; the add average excludes the opening position and quarters without price data. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.